ASTER-GUARDIANS
15.5.2023 15:28:35 CEST | Business Wire | Press release
Margaret Helen Shepherd from UK has been announced as the winner of the Aster Guardians Global Nursing Award 2023 in a prestigious award ceremony held at Queen Elizabeth II Centre in London. The winner was announced by Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare and the award was presented by Professor Jamie Waterall, Deputy Chief Public Health Nurse for the Office of Health Improvement & Disparities at Govt. of UK alongside Ms. Sheila Sobrany – President of Royal College of Nursing; Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare; and Mr. TJ Wilson – Executive Director and Group Head – Governance & Corporate Affairs, Aster DM Healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005491/en/
Margaret Helen Shepherd from the UK - Winner of the Aster Guardians Global Nursing Award 2023 (Photo: AETOSWire)
Launched on International Nurses Day in May 2021 by Aster DM Healthcare, with an aim to recognise the selfless contribution of nurses to millions of patients worldwide, Aster Guardians Global Nursing Award 2023 received an overwhelming response from nurses worldwide with over 52,000 nurses from 202 countries, a 116% growth from the last edition which had received 24,000 applications.
The award ceremony also saw a special video message from Dr. Tedros Adhanom Ghebreyesus – Director General of World Health Organisation being played to congratulate all the finalists and thank Aster DM Healthcare for the initiative.
On winning the award, Nurse Margaret said, “I am deeply humbled and grateful to receive the prestigious Aster Guardians Global Nursing Award. As healthcare professionals, we are privileged to be able to make a positive impact on the lives of our patients, and I feel blessed to be part of such a rewarding profession. This award not only recognises my personal achievements but also highlights the importance of nursing as a critical component of healthcare. Thank you to all my colleagues, mentors, and patients who have supported me throughout my career.”
Margaret has been dedicated to improving diabetes care through better diagnosis. She is the leading nurse for monogenic diabetes in the UK and provides advice to clinicians across the world regarding the management of this condition. She set up a national network of genetic diabetes nurses in 2002 to increase awareness of this condition (which is initially misdiagnosed in 80% of cases, resulting in patients being treated with unnecessary insulin injections). She was one of 70 national NIHR70@70 Senior Nurse Research Leaders (driving innovation and new roles to increase research awareness and engagement within clinical care) and has received the prestigious Florence Nightingale Foundation Leadership Scholarship.
Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “We are honoured to announce Ms Margaret Helen Shepherd from the United Kingdom as the winner of this year's Aster Guardians Global Nursing Award. She has exemplified the highest standards of patient care and dedication that is inspirational, and it deserves global recognition. Each one of the top 10 finalists have done phenomenal work and the Grand Jury had a tough time assessing and selecting the final winner. We are privileged to offer Aster Guardians Global Nursing Award as a platform to share and honor the accomplishments of exceptional nurses from around the globe.”
Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare said, “Aster Guardians Global Nursing Award is a small yet significant expression of gratitude that aligns with this year's International Nurses Day theme, ‘Our Nurses. Our Future’. Nurses ensure that patients receive high-quality care and often go beyond their call of duty to ensure that the right care is provided. This often helps them develop into other areas like research, innovation, mentorship, education, digitization among others as the stories of this year’s finalists and the winner have showcased. We as individuals and organizations must ensure that they receive the recognition they deserve, and this is where initiatives like Aster Guardians Global Nursing Award come into play. As a group, we will continue to support and celebrate the tireless efforts of nurses and put forth their inspiring stories of excellence.”
The rest of the 9 finalists, Cathy Cribben-Pearse from UAE, Christine Mawia Sammy from Kenya, Gloria Ceballo from Panama, Jincy Jerry from Ireland, Lilian Yew Siew Mee from Singapore, Michael Joseph Dino from Philippines, Shanti Teresa Lakra from India, Teresa Fraga from Portugal, and Wilson Fungameza Gwessa from Tanzania were also awarded with a monetary prize.
These nurses were selected through a stringent review process run by Ernst & Young LLP, a panel of Screening-Jury and the Grand Jury.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 30 hospitals, 125 clinics, 496* pharmacies, 20 labs and 157 patient experience centers in seven countries, including India. We reach out to all economic segments in the GCC states through our differentiated healthcare services across the “Aster”, “Medcare” and “Access” brands.
* Including 239 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005491/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom